Zomedica partners with IncellDx to help fight canine and human cancerDecember 21, 2018An assay agreement between two companies has been made to identify and enumerate circulating tumor cells (CTCs) from canine cancers.
SPONSORED CONTENTFind success with your parvovirus protocolDiscover our Canine Parvovirus Monoclonal Antibody: puppies treated with CPMA experienced a 93% real-world survival rate, and were able to head home from the clinic almost two days earlier.1,2 + Read More